NextCure, Inc. (NASDAQ:NXTC) Short Interest Up 48.9% in January

NextCure, Inc. (NASDAQ:NXTC) was the recipient of a large increase in short interest in January. As of January 15th, there was short interest totaling 48,377 shares, an increase of 48.9% from the December 31st total of 32,483 shares. Approximately 1.6% of the shares of the company are short sold. Based on an average trading volume of 32,544 shares, the short-interest ratio is currently 1.5 days. Based on an average trading volume of 32,544 shares, the short-interest ratio is currently 1.5 days. Approximately 1.6% of the shares of the company are short sold.

NextCure Stock Performance

NXTC stock traded up $0.08 during mid-day trading on Monday, hitting $10.93. 43,683 shares of the company were exchanged, compared to its average volume of 29,237. NextCure has a 1-year low of $2.69 and a 1-year high of $15.74. The firm’s 50 day simple moving average is $12.56 and its 200 day simple moving average is $8.82. The firm has a market cap of $38.36 million, a P/E ratio of -0.45 and a beta of 1.54.

NextCure (NASDAQ:NXTC) last announced its earnings results on Wednesday, November 5th. The company reported ($3.22) earnings per share for the quarter, topping analysts’ consensus estimates of ($4.06) by $0.84. On average, equities research analysts predict that NextCure will post -1.87 EPS for the current fiscal year.

Analysts Set New Price Targets

Several brokerages have issued reports on NXTC. Wall Street Zen raised shares of NextCure to a “hold” rating in a report on Saturday, December 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of NextCure in a report on Wednesday. Finally, LADENBURG THALM/SH SH upgraded shares of NextCure from a “neutral” rating to a “buy” rating and set a $18.00 price objective for the company in a research report on Friday, November 7th. Three research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $23.00.

Institutional Inflows and Outflows

An institutional investor recently raised its position in NextCure stock. Cable Car Capital LP boosted its holdings in NextCure, Inc. (NASDAQ:NXTC) by 13.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 758,141 shares of the company’s stock after purchasing an additional 88,040 shares during the period. Cable Car Capital LP owned about 28.29% of NextCure worth $349,000 as of its most recent filing with the Securities and Exchange Commission. Institutional investors and hedge funds own 42.65% of the company’s stock.

NextCure Company Profile

NextCure, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel immune modulators for the treatment of cancer and inflammatory diseases. Leveraging its proprietary Therapeutic Discovery Engine (TDE™), the company aims to identify, validate and optimize new targets in the immune response pathway. NextCure’s research platform integrates large‐scale proteomics and functional genomics to accelerate the progression of promising therapeutic candidates from early discovery through clinical development.

The company’s pipeline includes multiple product candidates in various stages of preclinical and clinical evaluation.